Among HER2 positive patients, exploratory analysis of the NeoALTTO trial have demonstrated a borderline significant decreased pCR rate for overweight/obese patients with HR + /HER2+ breast cancer (OR = 0.55, P = 0.053), but not in HR-/HER2+ breast cancer (OR = 1.3, P = 0.331)11. This evidence concerns the gene ERBB2 and breast carcinoma.